Aptevo Therapeutics (APVO) AI Stock Analysis

• Market Cap: $2.23M
• Dividend Yield: N/A
• Average Volume (3M): 5.78M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.38
• Revenue Growth: N/A
• EPS Growth: 83.04%
• Country: US
• Employees: 37
• Sector: Healthcare
• Sector Strength: 64
• Industry: Biotechnology
• EPS (TTM): -452.26
• Shares Outstanding: 3,223,214
• 10 Day Avg. Volume: 6,215,602
• 30 Day Avg. Volume: 5,782,761
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $21.00
• Price Target Upside: 2737.84% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Aptevo Therapeutics' stock score is significantly impacted by its challenging financial performance, marked by declining revenues, high leverage, and negative cash flows. The technical analysis indicates bearish momentum, while the valuation is weakened by persistent losses. However, promising developments in its oncology pipeline offer potential upside if successfully executed.

Aptevo Therapeutics Business Overview & Revenue Model

Company Description

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

How the Company Makes Money

Aptevo Therapeutics generates revenue through a combination of product development partnerships, licensing agreements, and research and development collaborations. A significant portion of its revenue comes from milestone payments, royalties, and upfront fees associated with its collaborations and licensing deals. For instance, Aptevo partners with other pharmaceutical companies to co-develop and commercialize its therapeutic candidates, which allows it to share development risks and benefits. Additionally, as its drug candidates progress through clinical trials and potentially reach the market, Aptevo stands to earn revenue from product sales, contingent on successful regulatory approvals and market adoption. Strategic partnerships and collaborations thus play a crucial role in Aptevo's revenue generation, supplementing its efforts to advance its proprietary platforms and therapeutic candidates.

Aptevo Therapeutics Financial Statement Overview

Summary

Aptevo Therapeutics faces significant financial challenges, with persistent losses, declining revenues, and negative cash flows. The company's high leverage and depleting asset base add to the risk profile, necessitating strategic actions to enhance financial health and ensure long-term viability.

Income Statement

Aptevo Therapeutics has shown a significant decline in revenue over the years, with zero revenue reported in the most recent periods. This impacts all margin metrics negatively, as net income remains negative, resulting in poor profitability indicators like gross profit margin and net profit margin. The revenue growth rate is also unfavorable, indicating a challenging operating environment.

Balance Sheet

The company's balance sheet reflects a high debt-to-equity ratio, indicating potential leverage risk. The equity ratio is relatively low, but the company maintains a positive stockholders' equity, suggesting some financial stability. However, the declining asset base and consistent losses could pose long-term sustainability challenges.

Cash Flow

Free cash flow is persistently negative, indicating cash burn issues, exacerbated by negative operating cash flow. While there are efforts to bolster cash flow through financing activities, the operating cash flow to net income ratio is unfavorable, highlighting inefficiencies in converting income to cash.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	3.11M	12.29M	4.31M
	Gross Profit
0.00	-567.00K	2.21M	-6.70M	-13.54M
	EBIT
-24.60M	-28.88M	-28.64M	-21.40M	-27.49M
	EBITDA
-24.60M	-28.31M	-27.74M	-20.26M	-26.09M
	Net Income Common Stockholders
-24.13M	-17.41M	42.67M	-27.31M	-18.45M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
8.71M	16.90M	22.64M	45.04M	39.98M
	Total Assets
15.59M	24.84M	34.22M	56.60M	53.55M
	Total Debt
4.63M	5.40M	9.54M	16.71M	27.41M
	Net Debt
-4.08M	-11.51M	-13.10M	-28.33M	-12.56M
	Total Liabilities
10.84M	12.62M	16.24M	55.38M	36.95M
	Stockholders Equity
4.75M	12.22M	17.97M	1.22M	16.59M
Cash Flow		Free Cash Flow
-23.79M	-11.73M	-21.05M	-22.39M	-29.41M
	Operating Cash Flow
-23.79M	-11.73M	-21.02M	-21.68M	-29.32M
	Investing Cash Flow
0.00	0.00	-29.00K	-713.00K	28.03M
	Financing Cash Flow
15.60M	6.00M	-2.62M	26.16M	23.87M

Aptevo Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.74
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APVO, the sentiment is Negative. The current price of 0.74 is below the 20-day moving average (MA) of 1.11, below the 50-day MA of 2.22, and below the 200-day MA of 7.56, indicating a bearish trend. The MACD of -0.45 indicates Negative momentum. The RSI at 31.74 is Neutral, neither overbought nor oversold. The STOCH value of 11.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APVO.

Aptevo Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.20B	3.26	-40.34%	2.93%	17.68%	1.94%
APVO	38 Underperform	$2.23M	―	-284.28%	―	―	83.04%
ENSC	32 Underperform	$3.49M	―	-471.82%	―	133.58%	82.60%
REVB	28 Underperform	$2.90M	―	-264.85%	―	―	-115.81%
ENVB	27 Underperform	$3.04M	―	-356.82%	―	―	82.47%

Aptevo Therapeutics Corporate Events

Aptevo Therapeutics Achieves Remission Success in AML Trial

On March 20, 2025, Aptevo Therapeutics announced that two additional patients achieved remission within 30 days in Cohort 2 of their RAINIER Phase 1b trial for acute myeloid leukemia (AML), following the success of Cohort 1 where 100% of patients achieved remission. This development highlights the potential efficacy of Aptevo’s drug pipeline, particularly mipletamig, in improving patient outcomes in AML, positioning the company favorably within the oncology sector.

Aptevo Therapeutics Showcases Promising Oncology Drug Pipeline

On February 11, 2025, Aptevo Therapeutics released an investor presentation detailing its current drug pipeline, showcasing its promising therapeutic candidates aimed at high-value oncology markets. The presentation highlighted ongoing clinical programs, including the RAINIER Phase 1b/2 trial for mipletamig, which displayed promising safety and efficacy results in treating acute myeloid leukemia (AML) patients. The diversified pipeline includes multiple candidates with the potential to address various solid malignancies, supporting Aptevo’s strategic growth and partnership opportunities.